Edwin Kwok


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Edwin Kwok is a partner in O’Melveny’s Hong Kong office. He is a versatile lawyer with extensive experience working with major investment banks, Chinese private companies, Chinese state-owned enterprises, real estate companies and biotech firms on their initial public offerings, cross-border acquisitions, public takeovers, privatizations, spin-offs, and follow-on offerings of equity and debt securities.

Edwin’s extensive experience includes advising on some of the most significant capital markets and mergers and acquisitions transactions in the Asia region.  He has advised on many securities offerings on the Hong Kong Stock Exchange, cross-border mergers and acquisition transactions, and equity-related corporate finance transactions. Recently, he has been advising issuers and underwriters on a number of pre-revenue biotech companies’ listings under the new biotech chapter of the Hong Kong Stock Exchange.



  • English
  • Cantonese
  • Mandarin


Bar Admissions

  • Hong Kong
  • England & Wales (non-practising)


  • University of Cambridge, LL.M.
  • University of Hong Kong, LL.B. (First Class Honours), P.C.LL.

ECM Transactions

  • Viva Biotech in its HK$1,521.5 million (approximately US$194 million) IPO on the Main Board of the Hong Kong Stock Exchange
  • Dexin China Holdings Company Limited in its US$190 million IPO on the Main Board of the Hong Kong Stock Exchange
  • Hua Medicine in its US$110 million Chapter 18A biotech company IPO sponsored by Goldman Sachs and CLSA Limited
  • China Securities (International) Corporate Finance Company Limited in the US$133 million IPO of mobile game publisher FingerTango Inc. on the Main Board of the Hong Kong Stock Exchange
  • China Securities (International) Corporate Finance Company in the US$40 million IPO of Digital Hollywood Interactive Limited on the Main Board of the Hong Kong Stock Exchange
  • Bank of Tianjin in its US$948 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange
  • State-owned shipping giant China Ocean Shipping (Group) Company, and China COSCO Holdings Company Limited and its associated companies in the landmark restructuring involving both China COSCO Group and China Shipping Group, comprising a series of asset acquisitions and disposals among China COSCO, China Shipping and their respective subsidiaries
  • CICC, Goldman Sachs, Morgan Stanley, Citigroup, China Merchants Securities and other underwriters in the US$925 million global offering and listing of H shares of Red Star Macalline Group Corporation Ltd., the largest home improvement and furnishings shopping mall operator in China, on the Main Board of the Hong Kong Stock Exchange
  • BOCOM International, ABCI, Qilu International, and other underwriters in the US$454 million global offering and listing of the H-shares of Guolian Securities Co. Ltd., one of the leading integrated securities firms in China, on the Main Board of the Hong Kong Stock Exchange
  • WH Group, the world's largest pork company with global leadership across key segments of the industry value chain, including packaged meats, fresh pork, and hog production, in its US$2.36 billion global offering and IPO
  • Haitong International, J.P. Morgan, Credit Suisse, Deutsche Bank, Citigroup and UBS, and other underwriters including HSBC, Nomura, Standard Chartered, and BOCOM International, in the US$1.68 billion H share IPO of Haitong Securities Co. Ltd
  • China Unicom in its US$23 billion merger with China Netcom by way of a scheme of arrangement
  • Morgan Stanley, Standard Chartered, BOCI Asia, BOCOM International, CCB International, and other underwriters in the US$87 million global offering and IPO of New Century Real Estate Investment Trust, the first solely China-based hotel REIT listing in the world
  • J.P. Morgan, as the sole sponsor and financial adviser, in China Daye Non-Ferrous Metals Mining Limited's deemed new listing and reverse takeover resulting from its RMB5.8 billion acquisition of Prosper Well Group Limited
  • Citigroup, UBS, and CIMB Securities Limited in the US$214 million global offering and IPO of Fu Shou Yuan International Group Limited, one of the largest providers of death care services in the PRC
  • Macquarie, BOCI Asia, BOCOM International, Haitong International, ICBC International, and ABCI in the US$202 million global offering and IPO of Logan Property Holdings Company Limited
  • Morgan Stanley, CITIC Securities Corporate Finance, ICBC International, and other underwriters in the US$130 million global offering and IPO of China VAST Industrial Urban Development Company Limited
  • CICC and GF Securities in the US$172 million global offering and IPO of H shares of China Aluminum International Engineering Corporation Limited
  • Morgan Stanley in the US$180 million global offering of Goodbaby International Holdings Limited
  • CICC, Deutsche Bank AG, Hong Kong Branch, Guotai Junan Securities and CLSA Limited, as the placing agents, in the HK$4.48 billion private H share placement of Sinopec Oilfield Service Corporation (SSC) on the Main Board of the Hong Kong Stock Exchange
  • Macquarie, HSBC and Nomura in the US$200 million global offering and IPO of Top Spring International Holdings, which was the first-ever listing to provide a mixed-media offering in Hong Kong
  • BOCOM International, Haitong International, KGI Capital, and GF Securities in the US$78 million global offering and spin-off listing of China New City Commercial Development Limited from Zhong An Real Estate
  • Goldman Sachs, Morgan Stanley, and HSBC in the spin-off and listing by introduction of Swire Properties
  • Merrill Lynch and Morgan Stanley in the HK$2.56 billion spin-off and global offering of Pou Sheng International (Holdings) Limited
  • Citigroup, JP Morgan, and Rothschild in the global offering and IPO of Trinity Limited
  • ASMC in its HK$700 million H share global offering and IPO sponsored by Goldman Sachs and BOCI

Mergers and Acquisitions

  • The buyer consortium in its US$300 million privatization offer for all the H shares of HK listed Shandong Luoxin Pharmaceutical by way of a voluntary conditional cash offer
  • Central China Real Estate Limited in its $132 million issuance of new shares to Joy Bright Investments Limited and third party subscribers by way of a whitewash waiver
  • Beijing Baoying Chuangfu Investment in its mandatory general offer for the outstanding H shares and domestic shares of Northeast Tiger Pharmaceutical (now known as Baytacare Pharmaceutical)
  • Goldman Sachs, Citigroup and China Merchants Securities in connection with the deemed new listing and placing of new shares by Tonic Industries (now known as China Merchants Land Limited)
  • Famous Commercial, a subsidiary of Gemdale (Asia) Investment Limited, in its acquisition of a stake in Hong Kong-listed Frasers Property (China) Limited (now known as Gemdale Properties and Investment Corporation Limited) for HK$1.65 billion by way of a mandatory general offer
  • Metro Victory Holdings in its mandatory general offer for the outstanding shares of Cinderella Media Group Limited (now known as KK Culture Holdings Limited)
  • Unitech Enterprises Group in its HK$258 million acquisition of approximately 61.56% of the entire issued share capital of Ford Glory Group (now known as Hua Long Jin Kong Company Limited) by way of a mandatory general offer
  • Nat-Ace Pharmaceutical in its approximately US$35 million acquisition of 52.79% of Perception Digital Holdings (now known as HongDa Financial Holding) by way of a mandatory general offer
  • Ever Billion Group Limited in its HK$765 million proposed acquisition of CASH Financial Services Group from Celestial Asia Securities Holdings Limited
  • China Oriental in its defense of a hostile takeover from Smart Triumph Corporation and its subsequent strategic alliance with ArcelorMittal
  • China Unicom in the US$6.3 billion sale of its CDMA business to China Telecom
  • Famous Commercial Ltd., a subsidiary of Shanghai-listed Gemdale Corporation, in its US$212 million acquisition of Frasers Property (China) Limited
  • Shunfeng Photovoltaic, as its US special counsel, in the US$482 million very substantial acquisition of the entire equity interests of Wuxi Suntech Power from its PRC administrator
  • Pacific Century CyberWorks, the real estate unit of PCCW Limited, in its proposed US$333 million privatization
  • G-Resouces Group in its fund raising in relation to the acquisition of the Martabe gold mining project
  • Tencent Holdings in its US$300 million investment in Digital Sky Technologies, one of the first-ever major outbound investment by an Internet company in China
  • Fortis Bank in its US$453 million acquisition of Pacific Century Insurance
  • Fosun International in various of its acquisitions of and investments into companies listed on the Hong Kong Stock Exchange